Miles Wang's AI drug discovery startup raises $200.0M (Jul 2026)
Reach the investors backing rounds like this
Backed by Lightspeed · verified emails and LinkedIn on Datapile
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B - TechCrunch
Miles Wang's new startup is focused on developing AI models for drug discovery. The company aims to leverage AI to find new uses for existing drugs and potentially those that previously failed in trials, which can lead to faster revenue generation compared to developing new drugs from scratch.
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B TechCrunch
| Sep 18, 2026 | Penelope Health | $100.0M | — | United Kingdom |
| Sep 18, 2026 | AbTx | $2.0M | Seed | France |
| Sep 18, 2026 | Angle Health | $600.0M | — | United States |
| Sep 18, 2026 | Aseptuva | $2.4M | Seed | Switzerland |
Find the investors behind rounds like this one
You just read who funded Miles Wang's AI drug discovery startup. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.